Vir Biotechnology, Inc.

VIR

Explore Our Financial Data > Companies > Vir Biotechnology, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
VIR
CIK0001706431
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158
Website vir.bio
Phone415-906-4324
CEOGeorge A. Scangos
Employees580

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$74.20 million
Pre-Tax Income$-523.10 million
Net Income$-521.96 million
Net Income to Common$-521.96 million
EPS$-3.83
View All
Balance Sheet
Cash$222.95 million
Assets$1.40 billion
Liabilities$248.43 million
Common Equity$1.15 billion
Liabilities & Equity$1.40 billion
View All
Cash Flow Statement
Net Income$-521.96 million
Cash From Operating Activities$-446.35 million
Cash From Investing Activities$499.37 million
Cash From Financing Activities$4.39 million
Change in Cash$57.40 million
View All
Calculations
NOPAT$-411.02 million
EBITDA$-574.96 million
Price to EarningsN/A
Price to Book$0.73
ROE-38.09%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

SAN FRANCISCO, April 24, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, a

Article Link

Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

Article Link

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company

Key Insights Given the large stake in the stock by institutions, Vir Biotechnology's stock price might be vulnerable to...

Article Link

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

SAN FRANCISCO, March 13, 2025--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1, the first trial of the program to be initiated, and ECLIPSE 2 are Phase 3 trials designed to provide the registrational data needed for submi

Article Link

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results

Vir Biotechnology, Inc. ( NASDAQ:VIR ) defied analyst predictions to release its annual results, which were ahead of...

Article Link